Parkinson’s Disease and Inflammatory Conditions
This activity took place on May 4, 2012 in St. Petersburg, FL. You must attend the live event and provide a unique access code to receive credit for this activity.
Ramon Rodriguez Cruz, MD
Clinical Associate Professor of Neurology, Director of Clinical Services, CMDNR Director
Clinical Trials Center for Neurological Disorders, University of Florida College of Medicine
John Carter, MD
Associate Professor of Medicine, Chief, Division of Rheumatology
Director of Innovative Therapies and Clinical Research, Division of Rheumatology
University of South Florida College of Medicine
Dr. Rodriguez discloses the following: Grants/Research Support: received research support from Abbott, Biotie Therapeutics, EMD-Serono, Huntington Study Group, Ipsen, Merz Pharmaceuticals, Allergan, National Parkinson Foundation, NIH/NINDS, Teva, Neuronova, but has no owner interest in any pharmaceutical company. Honoraria: Over the last 12 months, received honoraria from PeerView Institute for Medical Education, PRIME CME, Corporate Meeting Solutions, Merz Pharmaceuticals, Lundbeck, Teva and AllerganContractual Services: The University of Florida Clinic has contracts with Allergan for education services provided by Dr. Rodriguez, but he does not receive any personal compensation for these roles.
Dr. Carter has no relevant financial relationships to disclose.
At the conclusion of this application-based activity, participants will be able to:
- Describe possible therapeutic management strategies for persons with Parkinson’s disease.
- Demonstrate the ability to evaluate drug therapy in persons with Parkinson’s disease.
- Identify and recommend treatment for management of problems frequently encountered with long-term management of Parkinson’s disease.
- Discuss therapeutic management concerns for the non-ambulatory Parkinson’s disease patient.
- Assess the effect of drug management changes on Parkinson’s disease symptoms.
- Discuss the increasing utilization of biologics for inflammatory conditions within senior care settings.
- List the various biologic agents currently FDA-approved for treating inflammatory conditions, highlighting those approved for rheumatoid arthritis.
- Describe key clinical attributes of each biologic agent, including special considerations when utilized in the geriatric population.
- Outline integral components of a pharmaceutical care plan for geriatric patients on biologic agents.
- Identify clinical monitoring parameters for biologics that should be evaluated during consultant pharmacist medication regimen review.
Continuing Pharmacy Education
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application-based activity (UAN: 0203-9999-12-072-L01-P) is approved for 3.0 contact hours.
Release: May 4, 2012
Expiration: Jul 5, 2012